Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus LUXIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus LUXIQ.
ARAZLO vs LUXIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Topical: Apply a thin film to affected areas of the scalp twice daily (morning and evening) for 2 weeks; do not exceed 50 g per week.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal half-life: 3-5 hours; in renal impairment may extend to 8 hours.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal: 30% unchanged; biliary/fecal: 70% as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid